Satoshi Yuki

2.2k total citations
24 papers, 1.9k citations indexed

About

Satoshi Yuki is a scholar working on Organic Chemistry, Neurology and Molecular Biology. According to data from OpenAlex, Satoshi Yuki has authored 24 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Organic Chemistry, 8 papers in Neurology and 5 papers in Molecular Biology. Recurrent topics in Satoshi Yuki's work include Amyotrophic Lateral Sclerosis Research (6 papers), Electron Spin Resonance Studies (5 papers) and Free Radicals and Antioxidants (5 papers). Satoshi Yuki is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (6 papers), Electron Spin Resonance Studies (5 papers) and Free Radicals and Antioxidants (5 papers). Satoshi Yuki collaborates with scholars based in Japan, United States and Singapore. Satoshi Yuki's co-authors include Toshiaki Watanabe, Kyuya Kogure, Hideyuki Nishi, K. Abe, Mariko Egawa, Kenichi Saito, Kazutoshi Watanabe, Masahiko Tanaka, Manabu Hirai and Yorihiro Yamamoto and has published in prestigious journals such as Stroke, Brain Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Satoshi Yuki

21 papers receiving 1.9k citations

Peers

Satoshi Yuki

NEURO

PHYSI

Susana Cardoso Portugal

Tim Ashwood Sweden

Grigory G. Borisenko United States

Xingmiao Chen Hong Kong

R L Chase United States

B. Spinnewyn France

Kristine M. Robinson United States

Joo Eun Jung United States

David A. Beebe United States

Werner J. Geldenhuys United States

Susana Cardoso Portugal

Satoshi Yuki

1.2k ×2.5

177 ×0.4

NEURO

301 ×0.8

NEURO

128 ×0.3

924 ×2.9

PHYSI

Citations per year, relative to Satoshi Yuki Satoshi Yuki (= 1×) peers Susana Cardoso

Countries citing papers authored by Satoshi Yuki

Since Specialization

Citations

This map shows the geographic impact of Satoshi Yuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Yuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Yuki more than expected).

Fields of papers citing papers by Satoshi Yuki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Yuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Yuki. The network helps show where Satoshi Yuki may publish in the future.

Co-authorship network of co-authors of Satoshi Yuki

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Yuki. A scholar is included among the top collaborators of Satoshi Yuki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Yuki. Satoshi Yuki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yuki, Satoshi, et al.. (2024). Paraoxonase 1 ameliorates neurological symptoms and motor coordination impairment caused by cerebral ischemia-reperfusion injury. Biomedicine & Pharmacotherapy. 182. 117792–117792.

Hirai, Manabu, et al.. (2023). Long‐term safety of oral edaravone in Japanese patients with amyotrophic lateral sclerosis: Sub‐analysis of a global, open‐label, phase 3 study. Neurology and Clinical Neuroscience. 12(2). 95–99.

Watanabe, Kazutoshi, Masahiko Tanaka, Satoshi Yuki, Manabu Hirai, & Yorihiro Yamamoto. (2017). How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?. Journal of Clinical Biochemistry and Nutrition. 62(1). 20–38. 179 indexed citations

Fukunaga, Kenji, Kazutoshi Watanabe, Ryoichi Ando, et al.. (2013). 6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(24). 6928–6932. 24 indexed citations

Egi, Yasuhiro, et al.. (2011). MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model. Brain Research. 1410. 122–131. 34 indexed citations

Aoki, Masashi, Hitoshi Warita, Hideki Mizuno, et al.. (2011). Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Research. 1382. 321–325. 32 indexed citations

Egi, Yasuhiro, et al.. (2011). Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia. Brain Research. 1389. 169–176. 21 indexed citations

Araki, Tsutomu, K. Nishioka, Satoshi Yuki, & Kyuya Kogure. (2009). Vinconate prevents ischemic neuronal damage in the rat hippocampus. Acta Neurologica Scandinavica. 81(2). 173–176.

Watanabe, Kazutoshi, Yoshio Hayashi, Masaki Shinoda, et al.. (2008). 5-Aryl-imidazolin-2-ones as a scaffold for potent antioxidant and memory-improving activity. Bioorganic & Medicinal Chemistry Letters. 18(4). 1478–1483. 23 indexed citations

10.

Umemura, Kazuo, Katsuya Higo, Takeshi Sakata, et al.. (2007). Effects of Alteplase, a Thrombolytic Agent, in a Rat Photothrombotic Middle Cerebral Artery Occlusion Model. Pathophysiology of Haemostasis and Thrombosis. 36(5). 245–250. 4 indexed citations

11.

Watanabe, Kazutoshi, et al.. (2003). Structure–activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone). Redox Report. 8(3). 151–155. 55 indexed citations

12.

Watanabe, Toshiaki, et al.. (1997). General pharmacological studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), a novel radical scavenging agent. 25. 242–243. 7 indexed citations

13.

Yuki, Satoshi & Kyuya Kogure. (1997). The changes of LCGU and rCBF in the MCA occlusion-recirculation model in rats and the ameliorating effect of MCI-186, a novel free radical scavenger. Molecular and Chemical Neuropathology. 32(1-3). 123–128. 2 indexed citations

14.

Yamamoto, Toshihiro, Satoshi Yuki, Toshiaki Watanabe, et al.. (1997). Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Research. 762(1-2). 240–242. 190 indexed citations

15.

Nakai, H., et al.. (1997). Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.. PubMed. 281(2). 921–7. 205 indexed citations

16.

Yuki, Satoshi, et al.. (1996). Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.. Journal of Pharmacology and Experimental Therapeutics. 278(2). 780–785. 36 indexed citations

17.

Watanabe, Toshiaki, Satoshi Yuki, Mariko Egawa, & Hideyuki Nishi. (1994). Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions.. Journal of Pharmacology and Experimental Therapeutics. 268(3). 1597–1604. 414 indexed citations

18.

Nishi, Hideyuki, et al.. (1989). Effect of MCI-186 on brain edema in rats.. Stroke. 20(9). 1236–1240. 150 indexed citations

19.

Watanabe, Toshiaki, et al.. (1988). Preventive effect of MCI-186 on an experimental model of hemispheric brain edema in rats. The Japanese Journal of Pharmacology. 46. 287–287. 4 indexed citations

20.

Abe, K., Satoshi Yuki, & Kyuya Kogure. (1988). Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger.. Stroke. 19(4). 480–485. 325 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact